With a market capitalization (market cap) of $4.49B — a measure of how much the company is worth — Concentra Group Holdings Parent, Inc. is the 1506th most valuable company in Healthcare as of August 18, 2026. Shares trade at $35.05, down +1.35% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Concentra Group Holdings Parent, Inc. is a U.S.-based provider of occupational health solutions. The company delivers a comprehensive suite of occupational and consumer health services, encompassing treatment for workers' compensation injuries, urgent care, diagnostic clinical testing, preventative health measures, and employer-specific programs, along with wellness initiatives. These services are accessible through their network of occupational health centers and onsite clinics. Furthermore, Concentra offers specialized solutions like Concentra Telemed, a telemedicine platform for addressing work-related injuries and illnesses and supporting employer services; Concentra Pharmacy, providing pharmaceutical solutions; and Concentra Medical Compliance Administration, a third-party administrative service that assists employers in managing drug abuse testing programs for both regulated and non-regulated workforces. Established in 1979 and headquartered in Mechanicsburg, Pennsylvania, the company functions as a subsidiary of Select Medical Corporation.
Visit websiteAs of August 18, 2026, Concentra Group Holdings Parent, Inc. (CON) is worth $4.49B — this is its market capitalization, the total value of all its outstanding shares.
Concentra Group Holdings Parent, Inc.’s market cap is $4.49B, which ranks it #1506 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Concentra Group Holdings Parent, Inc. (CON) shares trade at $35.05, down 1.35% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Concentra Group Holdings Parent, Inc. trades at a price-to-earnings (P/E) ratio of 25.2, based on its latest share price and annual earnings per share.